<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384393</url>
  </required_header>
  <id_info>
    <org_study_id>ThisCART19</org_study_id>
    <nct_id>NCT04384393</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies</brief_title>
  <official_title>A Single Dose-escalation Study to Evaluate the Safety and Clinical Activity of Allogeneic Chimeric Antigen Receptor T Cells Targeting CD19 in Patients With Refractory or Relapsed B Cell Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundamenta Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundamenta Therapeutics, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T
      targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, nonrandomized, open-label study to evaluate the safety and clinical
      activity of ThisCART19 in patients with refractory or relapsed CD19 positive B cell
      malignancies, such as acute or chronic lymphocytic leukemia, lymphoma and etc. The dose range
      is 0.2-6 x 10^6 cells per kg body weight.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2020</start_date>
  <completion_date type="Anticipated">October 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities</measure>
    <time_frame>From infusion to Day 28</time_frame>
    <description>To assess adverse events as dose limiting toxicities as defined by the protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Remission</measure>
    <time_frame>At Day 28 after ThisCART19 infusion</time_frame>
    <description>Proportion of patients in whom with morphologic complete remission (CR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>For Acute Lymphoblastic Leukemia (ALL), Objective response rate(ORR) is the percentage of patients who achieve CR or chronic lymphocytic leukemia(CRi); for chronic lymphocytic leukemia (CLL) and lymphoma, ORR is the incidence of either a complete response (CR) or a partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Duration of Response (DOR) defined as the duration (days) from initial response to disease relapse, progression, or death due to any course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>From inclusion up to 1 year</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v5.0 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate of 2 Years</measure>
    <time_frame>At year 2</time_frame>
    <description>The rate of patients whom alive at year 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Related Mortality</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The mortality related with ThisCART19 infusion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>B Cell Malignancy</condition>
  <arm_group>
    <arm_group_label>ThisCART19 cells injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ThisCART19 cells</intervention_name>
    <description>0.2-6 x 10^6 CAR T cells per kg body weight.</description>
    <arm_group_label>ThisCART19 cells injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with relapsed or refractory CD19 positive acute or chronic lymphocytic
             leukemia, or lymphoma.

          2. No alternative treatment options deemed by investigator.

          3. Measurable or detectble disease at time of enrollment.

          4. Eastern cooperative oncology group (ECOG) performance status of ≤2.

          5. Cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by
             an echocardiogram (ECHO).

          6. Estimated life expectancy &gt; 12 weeks deemed by investigator.

          7. Serum creatinine ≤1.6 mg/dl and/or blood urea nitrogen(BUN) ≤ 1.5 mg/dl .

          8. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 5 upper
             limit of normal (ULN).

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Uncontrolled infection

          3. Active hepatitis B virus or hepatitis C virus infection.

          4. Patients who need steroids to control disease.

          5. Patients who accepted autologous stem-cell transplantation (ASCT) within 100 days.

          6. Patients with grade 2-4 graft-versus-host disease (GVHD), or deemed need to manage by
             investigator.

          7. History of Human Immunodeficiency Virus (HIV) infection.

          8. Patients with active central nervous system (CNS) involvement by malignancy.

          9. Patients combine with other disease cause neutrophil count (ANC) &lt; 750 per microlitre
             or platelet count (PLT)&lt; 50,000 per microlitre.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xingbing Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anhui Provincial Hospital, Anhui Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Li, Ph.D</last_name>
    <phone>+86-18662604088</phone>
    <email>jli@ctigen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling He</last_name>
    <phone>+86-18626100886</phone>
    <email>lhe@ctigen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anhui Provincial Hospital, Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingbing Wang</last_name>
      <phone>+86-18056075256</phone>
      <email>wangxingbing@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundamenta Therapeutice Co.,Ltd</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Li</last_name>
      <phone>+8618662604088</phone>
      <email>jli@ctigen.com</email>
    </contact>
    <contact_backup>
      <last_name>Ling He</last_name>
      <phone>+8618626100886</phone>
      <email>lhe@ctigen.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

